Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CelluJuve® for the Treatment of Moderate to Severe NLFs

NCT: NCT07545980 · RECRUITING

NCT IDNCT07545980
StatusRECRUITING
Start Date2026-04-29
Completion2028-07-31
SponsorSpiderwort Biotechnologies Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

Single-center, open-label proof of concept study assessing the safety and effectiveness of CelluJuve® for the treatment of moderate to severe NLFs

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑